IAMGOLD management commentary cites higher gold prices as driver of Q3 2026 revenue growth
Bitget2026/11/05 23:39- IAMGOLD management commentary reported third-quarter 2026 net earnings attributable to equity holders of USD 297 million, versus USD 139.4 million a year earlier.
- Revenue rose 21% to USD 856.5 million, driven by higher realized gold prices despite lower sales volumes.
- Attributable production fell to 186,900 ounces as lower Côté throughput, grades and recoveries outweighed gains at Westwood and Essakane.
- All-in sustaining costs increased to USD 2,184 per ounce sold from USD 1,956, reflecting higher royalties and sustaining capital spending.
- Operating cash flow rose to USD 461.1 million from USD 280.8 million, supported by higher revenue from stronger realized gold prices.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - Rocket Lab’s stock falls as quarterly loss exceeds expectations
BUZZ-Take-Two shares rise after raising annual revenue and profit forecasts
Itaúsa Q3 2026 recurring net profit rises 25% to R$ 5.06 billion year-on-year
The US FDA requires semaglutide, tirzepatide, and other GLP-1 drugs to include new warnings about the risk of eye disease.
NAION is an eye disease that can cause sudden, painless loss of vision, with some patients potentially experiencing permanent visual impairment. The drugs involved include products from Eli Lilly and Novo Nordisk. According to analysts at Citi, the incidence of NAION is relatively low, and given the significant benefits of GLP-1 drugs in weight control and blood sugar management, the actual impact on prescription behavior is expected to be limited. On Monday, the stock prices of Eli Lilly and Novo Nordisk increased, with the news not causing any significant impact on their share prices.
Crypto prices
More
